Important note: Information in this article was accurate in June 2006. The state of the art may have changed since the publication date.
 |
HIV Treatment Bulletin - Vol. 7, No. 6, June 2006
Simon Collins, HIV i-Base
Several studies presented data on new drugs interactions. Some of these studies had been presented at earlier meetings, and the summary table of interactions from EACS, ICAAC and CROI, published in the April issue of HTB [1] may be a useful additional guide in association with those reported in the Table 1 below.
| Table 1 – PK and drug interaction studies at 7th Intl PK Workshop, Lisbon | ||||
| ARV | Interaction | Results | Recommendation | Reference |
| Lopinavir/r 533 mg/133mg bid |
Nevirapine 200mg bid at steady state |
LPV/r Ctrough maintained above minimum target in 14/15 PI/NNRTI-naïve patients, but widely interpatient variability |
Increasing LPV/r dose to 533/133 is appropriate with NVP. TDM is recommended. Data needed on new Meltrex formulation of Kaletra. |
Else L et al. Abstract 67.[2] |
| TPV/r | Methadone (single dose 5mg at TPV/r steady state |
Methadone AUC. Cmax and C6H all decreased by ~50% ↓ (similar to other RTV- boosted PIs) |
Dose of methadone may need to be increased |
Sabo JP et al. Abstract 42.[3] |
| Etravirine (TMC-125) |
Sildenafil (Viagra) 50mg dose at TMC-125 steady state |
Sildenafil AUC. & Cmax decreased by 43% & 55% ↓ and active metabolite reduced by 59% & 75% ↓ TMC-125→ |
Dose administration of sildenafil should be tailored to individual response |
Schöller M et al. Abstract 45.[4] |
| TMC-278 (investigatoinal NNRTI) |
Rifampicin | TMC-278 AUC. Cmax and Cmin decreased by 80%. 69% & 89% ↓ |
TMC-278 and rifampicin should NOT be used together |
Van Heeswijk R et al. Abstract 74.[5] |
| TMC-278 (investigatoinal NNRTI) |
Ketoconazole | TMC-278 AUC. Cmax and Cmin increased by 49%. 30% & 76% ↑ |
Dose adjustment dependent on further studies |
Van Heeswijk R et al. Abstract 74.[5] |
| Brecanavir/ ritonavir (300/100mg BD) |
Atazanavir 300mg once-daily |
All increased: Brecanavir by 38% ritonavir by 56%, and atazanavir by 44% |
Consider does reduction of atazanavir. (Confirm with TDM) |
Ford S et al. Abstract 76.[6] |
| LPV/r | ezitimibe | No significant interaction | Can be coadministered | Moltó J et al. Abstract 50.[7] |
References
Unless stated otherwise, all references are to the Programme and Abstracts of the 7th International Workshop on Clinical Pharmacology of HIV Therapy, 20-22 April 2006, Lisbon. Available online at: http://www.hivpresentation.com
| 1. | Pharmacology and drug interaction studies in adults: summary table from CROI, ICAAC and EACS conferences. HIV Treatment Bulletin April 2006. http://www.i-base.info/htb/v7/htb7-4/Pharmacology.html |
| 2. | Else L et al. The pharmacokinetics (PK) of lopinavir/ritonavir (LPV/r) 533/133 mg bid plus nevirapine (NVP) (200 mg bid) in adult HIV-1 infected individuals. Abstract 67. |
| 3. | Sabo J et al. Stereoselective pharmacokinetics (PK) of methadone after coadministration with steady-state tipranavir/ritonavir 500/200 mg bid (TPV/r) in healthy volunteers. Abstract 42. |
| 4. | Schöller, M et al. Effect of TMC125 on sildenafil pharmacokinetics Abstract 45. |
| 5. | van Heeswijk R et al. The effects of CYP3A4 modulation on the pharmacokinetics of TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI). Abstract 74. |
| 6. | Ford S, Murray S, Anderson M et al. Brecanavir/ritonavir and atazanavir/ritonavir increased following repeat co-administration. Abstract 76. |
| 7. | Moltó J et al. The effect of ezetimibe (EZT) on the steady-state pharmacokinetics of lopinavir (LPV). Abstract 50. |
2006-06-10
IB060706-14
©2006. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.